PRESS RELEASES

2018

Alector Strengthens Board of Directors with Appointments of David Wehner, Richard Scheller and Louis Lavigne
Business Wire, Nov 16, 2018

Alector Initiates Phase 1 Trial of AL002 for the Treatment of Patients with Alzheimer’s Disease
Business Wire, Nov 15, 2018

Alector Initiates Phase 1 Trial of AL001 for the Treatment of Frontotemporal Dementia
Business Wire, Sept 19, 2018

Alector Receives Orphan Drug Designation from the U.S. FDA for AL001 for the Treatment of Frontotemporal Dementia
Business Wire, Aug 8, 2018 

Alector to Present at Cowen and Company 38th Annual Health Care Conference
BusinessWire, Mar 8, 2018


 

2017

Alector and AbbVie Announce Collaboration to Advance Immune Therapies for Patients with Alzheimer's Disease
PR Newswire, Oct 24, 2017